• Je něco špatně v tomto záznamu ?

Endocrinological aspects of pituitary adenoma surgery in Europe

D. Netuka, A. Grotenhuis, N. Foroglou, F. Zenga, S. Froehlich, F. Ringel, N. Sampron, N. Thomas, M. Komarc, M. Kosák, M. Májovský

. 2022 ; 12 (1) : 6529. [pub] 20220420

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018745

Hormone-secreting adenomas are treated in many neurosurgical centers within Europe. The goal of the survey is to understand variance in practice management of pituitary tumors amongst neurosurgical centers. A list of departments performing pituitary surgery was created. The survey consisted of 58 questions. This study focuses on neurosurgical care of hormone-secreting adenomas. For analysis, the departments were divided into four subgroups: academic/non-academic, high-volume/low-volume, "mainly endoscopic/mainly microscopic practice" and geographical regions. Data from 254 departments from 34 countries were obtained. Most centers surgically treat 1-5 hormone-secreting adenomas per year. In prolactinomas this is the case in 194 centers, (76.4%), in GH-secreting adenomas: 133 centers, (52.4%), ACTH-secreting adenomas: 172 centers, (69.8%). Surgery as a primary treatment of prolactinomas is considered in 64 centers (25.2%). In 47 centers (18.8%), GH-secreting microadenomas are often treated pharmacologically first. Debulking surgery for an invasive GH-secreting adenoma in which hormonal remission is not a realistic goal of the surgery and the patient has no visual deficit surgery is always or mostly indicated in 156 centers (62.9%). Routine postoperative hydrocortisone replacement therapy is administered in 147 centers (58.6%). Our survey shows that in most centers, few hormone-secreting adenomas are treated per year. In about 25% of the centers, prolactinoma surgery may be regarded as first-line treatment; in about 20% of the centers, medical treatment is the first-line treatment for GH-secreting adenomas. Pretreatment for ACTH-secreting adenomas is routinely used in 21% of centers. This survey may serve as plea for neurosurgical care centralization of hormone-secreting adenomas.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018745
003      
CZ-PrNML
005      
20220804135051.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-022-10300-1 $2 doi
035    __
$a (PubMed)35444169
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Netuka, David $u Department of Neurosurgery and Neurooncology, First Faculty of Medicine, Charles University and Military University Hospital, U Vojenske Nemocnice 1200, 169 02, Prague 6, Czech Republic. Netuka.david@gmail.com $1 https://orcid.org/0000000186094789 $7 xx0061783
245    10
$a Endocrinological aspects of pituitary adenoma surgery in Europe / $c D. Netuka, A. Grotenhuis, N. Foroglou, F. Zenga, S. Froehlich, F. Ringel, N. Sampron, N. Thomas, M. Komarc, M. Kosák, M. Májovský
520    9_
$a Hormone-secreting adenomas are treated in many neurosurgical centers within Europe. The goal of the survey is to understand variance in practice management of pituitary tumors amongst neurosurgical centers. A list of departments performing pituitary surgery was created. The survey consisted of 58 questions. This study focuses on neurosurgical care of hormone-secreting adenomas. For analysis, the departments were divided into four subgroups: academic/non-academic, high-volume/low-volume, "mainly endoscopic/mainly microscopic practice" and geographical regions. Data from 254 departments from 34 countries were obtained. Most centers surgically treat 1-5 hormone-secreting adenomas per year. In prolactinomas this is the case in 194 centers, (76.4%), in GH-secreting adenomas: 133 centers, (52.4%), ACTH-secreting adenomas: 172 centers, (69.8%). Surgery as a primary treatment of prolactinomas is considered in 64 centers (25.2%). In 47 centers (18.8%), GH-secreting microadenomas are often treated pharmacologically first. Debulking surgery for an invasive GH-secreting adenoma in which hormonal remission is not a realistic goal of the surgery and the patient has no visual deficit surgery is always or mostly indicated in 156 centers (62.9%). Routine postoperative hydrocortisone replacement therapy is administered in 147 centers (58.6%). Our survey shows that in most centers, few hormone-secreting adenomas are treated per year. In about 25% of the centers, prolactinoma surgery may be regarded as first-line treatment; in about 20% of the centers, medical treatment is the first-line treatment for GH-secreting adenomas. Pretreatment for ACTH-secreting adenomas is routinely used in 21% of centers. This survey may serve as plea for neurosurgical care centralization of hormone-secreting adenomas.
650    12
$a adenom $x patologie $x chirurgie $7 D000236
650    _2
$a adrenokortikotropní hormon $7 D000324
650    _2
$a lidé $7 D006801
650    12
$a nádory hypofýzy $x patologie $x chirurgie $7 D010911
650    12
$a prolaktinom $x patologie $x chirurgie $7 D015175
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Grotenhuis, André $u Department of Neurosurgery, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
700    1_
$a Foroglou, Nicolas $u 1St Department of Neurosurgery, Aristotle University of Thessaloniki, Thessaloniki, Greece
700    1_
$a Zenga, Francesco $u Department of Neuroscience "Rita Levi Montalcini", Neurosurgery Unit, University of Turin, Turin, Italy
700    1_
$a Froehlich, Sebastien $u Department of Neurosurgery, Lariboisière University Hospital, Paris, France
700    1_
$a Ringel, Florian $u Department of Neurosurgery, Johannes Gutenberg-Universität Mainz, Mainz, Germany
700    1_
$a Sampron, Nicolas $u Neurosurgery Department, University Hospital Donostia, San Sebastian, Spain
700    1_
$a Thomas, Nick $u Department of Neurosurgery, Kings College, London, UK
700    1_
$a Komarc, Martin $u Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic
700    1_
$a Kosák, Mikuláš $u Department of Internal Medicine, First Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic
700    1_
$a Májovský, Martin $u Department of Neurosurgery and Neurooncology, First Faculty of Medicine, Charles University and Military University Hospital, U Vojenske Nemocnice 1200, 169 02, Prague 6, Czech Republic
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 12, č. 1 (2022), s. 6529
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35444169 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135044 $b ABA008
999    __
$a ok $b bmc $g 1822387 $s 1169988
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c 1 $d 6529 $e 20220420 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

    Možnosti archivace